Adamgammadex

Authors

  • Alba Porto Soto Resident of Anesthesiology and Resuscitation. Vall d’Hebron University Hospital - Barcelona
  • Elena Vilardell Ortiz Assistant of Anesthesiology and Resuscitation. Vall d’Hebron University Hospital - Barcelona
  • Anna Abad Torrent Assistant of Anesthesiology and Resuscitation. Vall d’Hebron University Hospital - Barcelona

DOI:

https://doi.org/10.30445/rear.v16i12.1295

Keywords:

Adamgammadex, Rocuronium, neuromuscular block, reversal

Abstract

Adamgammadex is a new agent for reversing neuromuscular blockade induced by rocuronium or vecuronium. Due to its higher molecular weight, it requires a higher dose than sugammadex. Clinical studies in China suggest that it is well tolerated and comparable to sugammadex in recovering a TOF ratio ≥ 0.9 within 5 minutes, with fewer adverse effects such as anaphylaxis, recurarisation, bradycardia, and laryngospasm. However, further studies are needed to confirm its efficacy and safety.

References

- Brull SJ, Murphy GS. Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness. Anesth Analg. julio de 2010;111(1):129-40.

- Hunter JM, Blobner M. Under-dosing and over-dosing of neuromuscular blocking drugs and reversal agents: beware of the risks. Br J Anaesth. marzo de 2024;132(3):461-5.

- Stäuble CG, Blobner M. The future of neuromuscular blocking agents. Curr Opin Anaesthesiol. agosto de 2020;33(4):490-8.

- FDA approves Bridion to reverse effects of neuromuscular blocking drugs used during surgery. 2015

- Qi, Y. M., Qi, Y. B., Yu, B. C., Lao, Q. C., Li, C. Q., Zhu, D. F., & Jie, Q. Screened adamgammadex for reversing rocuronium-induced neuromuscular blockade with greater safety. Chin J Pharmacol Toxicol. 2018;32:515-26.

- Schulte E, Arlt SP. What Kinds of Dogs Are Used in Clinical and Experimental Research? Animals (Basel). 8 de junio de 2022;12(12):1487.

- Teame T, Zhang Z, Ran C, Zhang H, Yang Y, Ding Q, et al. The use of zebrafish (Danio rerio) as biomedical models. Anim Front. julio de 2019;9(3):68-77.

- Jiang Y, Zhang Y, Xiang S, Zhao W, Liu J, Zhang W. Safety, tolerability, and pharmacokinetics of adamgammadex sodium, a novel agent to reverse the action of rocuronium and vecuronium, in healthy volunteers. Eur J Pharm Sci. 1 de enero de 2020;141:105134.

- Zhao Y, Chen S, Huai X, Yu Z, Qi Y, Qing J, et al. Efficiency and Safety of the Selective Relaxant Binding Agent Adamgammadex Sodium for Reversing Rocuronium-Induced Deep Neuromuscular Block: A Single-Center, Open-Label, Dose-Finding, and Phase IIa Study. Front Med (Lausanne). 2021;8:697395.

- Zhao Y, Chen S, Xie W, Zhang X, Chen G, Ji F, et al. Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular blockade: A multicenter, randomized, phase IIb study. Clin Transl Sci. enero de 2024;17(1):e13691.

- Jiang Y, Zhang Y, Zhu Z, Huang Y, Zhou D, Liu J, et al. Comparison of the Efficacy and Safety of Adamgammadex with Sugammadex for Reversal of Rocuronium-Induced Neuromuscular Block: Results of a Phase II Clinical Trial. J Clin Med. 25 de noviembre de 2022;11(23):6951.

- Zhang Y, Jiang Y, Lei Q, Li C, Jin S, Wang Q, et al. Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block. Br J Anaesth. enero de 2024;132(1):45-52.

Downloads

Published

2025-01-02

How to Cite

Porto Soto, A., Vilardell Ortiz, E., & Abad Torrent, A. (2025). Adamgammadex. Revista Electrónica AnestesiaR, 16(12). https://doi.org/10.30445/rear.v16i12.1295

Issue

Vol. 16 No. 12 (2024): Revista Electrónica de AnestesiaR

Section

Review articles

License

Copyright (c) 2025 Revista Electrónica AnestesiaR

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Envío y derechos de autor

 

Most read articles by the same author(s)

1 2 > >>